Peanut Allergy Treatment Market Report 2026

Peanut Allergy Treatment Market Overview

• Peanut Allergy Treatment market size has reached to $0.5 billion in 2025 • Expected to grow to $0.8 billion in 2030 at a compound annual growth rate (CAGR) of 9.7% • Growth Driver: Driving Growth In The Peanut Allergy Treatment Market Through Research And Development Investment • Market Trend: Advancements In Peanut Allergy Treatment Focuses On Anti-IgE Monoclonal Antibodies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Peanut Allergy Treatment Market?

Peanut allergy treatment refers to various medical approaches designed to manage and reduce the severity of allergic reactions to peanuts. These treatments involve various approaches, such as epicutaneous immunotherapy and biologic therapies aimed at desensitizing individuals to peanuts and mitigating allergic reactions. The main drug classes of peanut allergy treatment are antihistamines, immunotherapies, epinephrine, and others. Antihistamines refer to medications that alleviate allergy symptoms by blocking the action of histamine, a substance released by the immune system during allergic reactions. The drugs are administered through injectables, oral, and others, It is distributed through retail pharmacies, hospital pharmacies, and others.

What Is The Peanut Allergy Treatment Market Growth Forecast?

The peanut allergy treatment market size is expected to see strong growth in the next few years. It will grow to $0.8 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to advancements in immunotherapy technologies, increasing approvals of disease-modifying treatments, rising demand for preventive allergy care, expansion of biologics targeting allergic pathways, growing investment in food allergy research. Major trends in the forecast period include rising adoption of oral immunotherapy for peanut desensitization, growing use of epicutaneous immunotherapy patches, increased integration of biologic therapies in allergy treatment, expansion of pediatric-focused peanut allergy treatments, greater emphasis on long-term allergy management solutions.

Global Peanut Allergy Treatment Market Segmentation

1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes 2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration 3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels Subsegments: 1) By Antihistamines: Oral Antihistamines, Topical Antihistamines 2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT) 3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers 4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids

What Is The Driver Of The Peanut Allergy Treatment Market?

The investment in research and development of allergy treatments is expected to propel the growth of the peanut allergy treatment market going forward. Research and development (R&D) investment refers to the financial resources allocated by companies, organizations, or governments toward activities aimed at innovation, product development, and technological advancement. The investment in research and development for allergy treatments is crucial for advancing peanut allergy therapies. This investment fosters the creation of innovative immunotherapies and desensitization techniques, which aim to reduce allergic reactions and improve the quality of life for those affected by peanut allergies. For instance, in January 2024, the Victorian Government announced a strategic $12 million investment in Aravax, an Australia-based clinical-stage biotechnology company, to significantly advance global peanut allergy treatment. This funding is part of a broader $66 million round aimed at developing Aravax's innovative immunotherapy, PVX108. This initiative has secured Phase 2 trial approvals from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), underscoring its potential impact on public health worldwide. Therefore, investment in research and development of allergy treatments is driving the growth of the peanut allergy treatment industry.

Key Players In The Global Peanut Allergy Treatment Market

Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc, Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd, Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.

Global Peanut Allergy Treatment Market Trends and Insights

Major companies operating in the peanut allergy treatment market are focusing on the development of biologic therapies, such as anti-IgE monoclonal antibodies, to offer more targeted and effective solutions for peanut allergy management, aiming to improve patient outcomes and quality of life. Anti-IgE monoclonal antibodies are a type of therapeutic agent designed to target and neutralize immunoglobulin E (IgE) antibodies in the body. For instance, in February 2024, Novartis Pharmaceuticals Corporation, a Switzerland-based pharmaceutical company, received approval from the Food and Drug Administration (FDA) for Xolair (omalizumab). This medication is intended to reduce allergic reactions, including anaphylaxis, in patients aged 1 year and older with IgE-mediated food allergies. The approval was based on data from the NIH-sponsored Phase III OUtMATCH study, which showed significant improvement in food allergy tolerance among patients treated with Xolair compared to those who received a placebo.

What Are Latest Mergers And Acquisitions In The Peanut Allergy Treatment Market?

In September 2023, Stallergenes Greer International AG, a Switzerland-based provider of allergen immunotherapy products, acquired the peanut allergy drug Palforzia from Nestlé S.A. for an undisclosed amount. Stallergenes Greer's acquisition of Palforzia represents a notable expansion of the company's anti-allergy portfolio, augmenting its suite of approved products designed to address a spectrum of allergies, such as grasses, mites, and trees. Nestlé S.A. is a Switzerland-based provider of food and beverage products and drugs for peanut allergy treatment.

Regional Insights

North America was the largest region in the peanut allergy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Peanut Allergy Treatment Market?

The peanut allergy treatment market consists of revenues earned by entities by providing services such as diagnostic testing, personalized treatment plans, oral immunotherapy sessions, patient education and counseling, monitoring of allergic reactions, and access to emergency care. The market value includes the value of related goods sold by the service provider or included within the service offering. The peanut allergy treatment market also includes sales of allergy drops, allergy tablets, and peanut allergen extract. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Peanut Allergy Treatment Market Report 2026?

The peanut allergy treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the peanut allergy treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.